We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Orogen | LSE:ORE | London | Ordinary Share | GB00BYXD4566 | ORD 0.01P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.70 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jan 2020 to Jan 2025
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014, AS AMENDED ("MAR"). ON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE ("RIS"), THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
DiscovOre plc
(To be renamed Oscillate plc)
AQSE: ORE
(“DiscovOre plc” or the “Company”)
All Resolutions passed at General Meeting, including a broadened investment policy to include Medical Psychedelics, Change of Name & Change of TIDM to, AQSE: MUSH
The Company is pleased to announce that at the General Meeting of Shareholders held today, all resolutions were duly passed.
The Company’s name will change to Oscillate plc and the change of name will be effective once Companies House has issued a certificate of change of name (“The Certificate”). A further announcement confirming the change of name will be made in due course. Upon issue of the Certificate, the Company’s ordinary shares, shall be traded on AQSE Growth Market under the ticker “MUSH”. There will be no change to the ISIN number.
The Company’s investment strategy will be broadened to include investment in Medical Psychedelic opportunities where consistent with the Company’s legal opinion and will be subject to certain review and conditions with the Company’s counsel. Upon conclusion of today’s General Meeting, DiscovOre plc (to be renamed “Oscillate plc”) will maintain an investment strategy covering, medical psychedelics, medical cannabis and special situations.
The Company has also updated the corporate website/domain to reflect the name change and broadened investment strategy, www.oscillateplc.com
DiscovOre plc,
London, 13th July 2021
The Directors of the Company, who have issued this RIS announcement after due and careful enquiry, accept responsibility for its content.
Enquiries
Company:
Burns Singh Tennent-Bhohi (Director)
Conrad Windham (Director)
Direct Office Line: +44 (0) 20 3778 0755
Corporate Adviser:
Peterhouse Capital Limited
Guy Miller & Mark Anwyl
Telephone: +44 (0) 20 7220 9796
Copyright y 13 PR Newswire
1 Year Orogen Gold Chart |
1 Month Orogen Gold Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
